CN215018250U - Degradable hemostatic bag capable of carrying medicine - Google Patents
Degradable hemostatic bag capable of carrying medicine Download PDFInfo
- Publication number
- CN215018250U CN215018250U CN202022964810.2U CN202022964810U CN215018250U CN 215018250 U CN215018250 U CN 215018250U CN 202022964810 U CN202022964810 U CN 202022964810U CN 215018250 U CN215018250 U CN 215018250U
- Authority
- CN
- China
- Prior art keywords
- hemostatic
- bag
- cavity
- degradable
- sealing door
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The utility model belongs to the technical field of medical instruments, and particularly discloses a degradable hemostatic bag capable of carrying medicine, which is an airbag body with a cavity, wherein a sealing door is arranged at the opening of the cavity; the bag body and the sealing door are made of hemostatic materials, and the cavity is used for placing medicines. Compared with a single hemostatic material, the hemostatic bag can be used as a carrier of a medicament, a certain proportion of the medicament is selected to be added into a bag cavity according to conditions in the using process, the bag body is placed on a surgical wound after surgery, the hemostatic material reduces bleeding of the wound until the wound stops, and meanwhile, along with degradation of the hemostatic material, the medicament is slowly released to act on the surgical wound to perform local chemotherapy on residual tumor cells so as to prevent recurrence and metastasis of tumors. Therefore, the utility model organically combines the hemostasis and anti-tumor effects, and is suitable for other operations besides the anti-tumor operation.
Description
Technical Field
The utility model belongs to the technical field of medical instrument, a degradable hemostasis bag that can carry medicine is related to.
Background
The incidence and mortality of malignant tumors have increased dramatically in recent years. The operation treatment is the first choice treatment mode of the tumor patients at present, but doctors cannot identify whether tumor cells are remained or not through naked eyes in the operation process, and meanwhile, part of tumors are late in stage, large in size and local in infiltration, so that the tumor cells cannot be completely resected in the operation process, and part of tumor tissues are remained, and the risk of postoperative tumor recurrence and metastasis is greatly increased.
In the process of surgical excision of a tumor body, bleeding is inevitable, and bleeding of a wound surface and bleeding of a broken end of a blood vessel are effectively stopped by adopting conventional methods such as electrocoagulation, compression, ligation and suture. But bleeding is still possible after the operation, and the application of the excellent hemostatic material can reduce the bleeding complication and death after the operation.
At present, in the clinical operation process, chemotherapy drugs are directly implanted to stimulate intestinal canals and local tissues, and the problems of improper placement, rapid drainage along with drainage fluid, short local action time and the like exist.
At present, no report of a degradable hemostatic material capable of carrying chemotherapeutic drugs exists clinically, so that the design of a degradable hemostatic material capable of carrying chemotherapeutic drugs is imperative clinically.
SUMMERY OF THE UTILITY MODEL
In order to overcome the defects existing in the prior art, the utility model aims to provide a degradable hemostatic bag capable of carrying medicine, which solves the problem that the prior hemostatic function and the killing of harmful histiocytes can not be combined.
The utility model discloses a realize through following technical scheme:
a degradable hemostatic bag capable of carrying a medicament is a bag body with a cavity, and a sealing door is arranged at an opening of the cavity;
the bag body and the sealing door are made of hemostatic materials, and the cavity is used for placing medicines.
Further, the capsule body is obtained by freeze-drying hydroxyethyl cellulose.
Further, the shape of the capsule body is a cuboid or an ellipsoid.
Further, when the utricule is the cuboid, the edge of cuboid all is prefabricated with the fillet.
Further, the sealing door is hinged with the bag body.
Further, the sealing door is detachably connected with the bag body.
Further, the wall thickness of utricule is 2 ~ 4 mm.
Further, the volume of the cavity is 0.2-1 cm3。
Compared with the prior art, the utility model discloses following profitable technological effect has:
the utility model discloses a degradable hemostatic bag capable of carrying medicine, which is an airbag body with a cavity, wherein a sealing door is arranged at the opening of the cavity, the airbag body and the sealing door are made of hemostatic materials, and the cavity is internally used for placing medicine. Simple structure, the medicine in the cavity can kill local remaining tumor cells, and the utricule has hemostatic effect, and biocompatibility is good, unites two into one hemostatic function and the function of killing local remaining tumor cells. Compared with a single hemostatic material, the hemostatic bag can be used as a carrier of a medicament, different medicaments are selected to be added into a bag cavity according to conditions in the using process, the bag body is placed on a surgical wound surface in an operation, the hemostatic material reduces bleeding of the wound surface until the wound surface stops, and meanwhile, along with degradation of the hemostatic material, the medicament is slowly released to act on the surgical wound surface to perform local chemotherapy on residual tumor cells so as to prevent relapse and metastasis of tumors. Therefore, the utility model organically combines the hemostatic and antitumor effects, and the capsule body effectively wraps the chemotherapeutic drug, so that the drug can not directly contact human tissues and body fluid, reduces local stimulation, and can not be discharged along with local drainage fluid, thereby slowly releasing the drug. Besides being used for anti-tumor operations, the degradable hemostatic bag capable of carrying the medicine can also be added with other medicines, and is suitable for other operations.
Furthermore, the capsule body is obtained by freeze-drying hydroxyethyl cellulose, the principle is that liquid is frozen into a solid state at low temperature, then the water in the liquid state is directly sublimated into a gaseous state without passing through the liquid state under the vacuum condition, and finally the dehydration technology of the material has no influence on the components of the material, thereby ensuring the hemostasis function of the capsule body.
Further, when the bag body adopts structures with edges such as a cuboid, the edges are rounded, and the tissues around the human body are prevented from being damaged.
Drawings
FIG. 1 is a schematic view of a degradable hemostatic sac capable of carrying drugs according to the present invention;
FIG. 2 is a photograph of the rat liver wound bleeding model construction and hemostasis process;
FIG. 3 is a comparison of the hemostatic effect of the experimental group, the gauze group and the blank group in the liver bleeding model of rats; (a) the time of hemostasis is shown in three groups, and the blood loss is shown in three groups.
Wherein: 1 is a capsule body and 2 is a cavity.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings:
as shown in fig. 1, the utility model discloses a degradable hemostatic bag capable of carrying medicine, which is a bag body 1 with a cavity 2, and a sealing door is arranged at the opening of the cavity 2; the capsule body 1 and the sealing door are made of hemostatic materials, and the cavity 2 is used for placing medicines.
The outer capsule wall is made of hydroxyethyl cellulose through freeze drying. The principle is that the liquid is frozen into a solid state at low temperature, then the water in the liquid state is directly sublimated into a gaseous state without passing through the liquid state under the vacuum condition, and finally the dehydration technology of the material has no influence on the components of the material, thereby ensuring the hemostasis function of the capsule body 1.
The degradable hemostatic bag is cuboid or ellipsoid in appearance, and other shapes can also be adopted.
Specifically, the hemostatic material is one or more of cellulose, chitosan, gelatin and fibrin glue.
Specifically, the drug carried by the capsule cavity adopts any one of 5-fluorouracil, cisplatin, carboplatin, adriamycin and bleomycin.
Specifically, the wall thickness of the bag body 1 is 2-4 mm, and the volume of the bag cavity is 0.2-1 cm3。
The operation of malignant tumor patients is taken as an example to illustrate the function of the degradable hemostatic sac capable of carrying the medicine of the utility model:
in the operation process of malignant tumor patients, 5-fluorouracil is added into the cavity 2 of the capsule body 1, then the capsule body 1 is placed on the operation wound, and the outer capsule wall has the hemostatic effect to reduce the bleeding of the wound until the wound stops. Meanwhile, with the degradation of the outer capsule wall, the chemotherapeutic drug is slowly released to act on the wound surface of the tumor resection, and the residual tumor cells are subjected to local chemotherapy.
It is right that the utility model discloses the verification of effect:
15 rats weighing 180-.
After a rat is anesthetized by injecting chloral hydrate into the abdominal cavity, fixing limbs, enabling the abdomen to face upwards, shaving and taking the hair of the rat at the abdomen, disinfecting the abdomen with 75% alcohol, cutting the abdomen to find the liver of the rat, cutting a wound on one side leaf of the liver, wherein the length of the wound is about 1cm, the depth of the wound is about 0.5cm, slightly wiping off blood on the wound after the rat freely bleeds for 5s, pressing a hemostatic material on the wound, starting timing, slightly uncovering the hemostatic material at intervals of 15 s, observing whether the wound bleeds continuously, if the bleeding continuously, continuously pressing the hemostatic until the bleeding stops, and recording the hemostatic time. And a sterile cotton ball is used to collect the bleeding which is not combined with the hemostatic material in the hemostasis process, which is shown in the specific process of figure 2. Before and after operation, the sample and the cotton ball are respectively weighed, and the bleeding time and the blood loss are calculated. Each group was repeated 5 times and the average value was taken. The specific results are shown in FIG. 3.
In fig. 3, it can be seen that the experimental group is very different from the medical gauze group and the blank group in the rat liver bleeding model. As shown in FIG. 3(a), from the viewpoint of hemostasis time, the hemostasis time of the experimental group is significantly shorter than that of the other two groups, the experimental group is 2.7 + -0.5 min, the common gauze group is 4.2 + -0.4 min, the blank control group is 5.3 + -0.7 min, and the difference is statistically significant (P < 0.05). As shown in FIG. 3(b), the blood loss of the experimental group was 1.21. + -. 0.1g from the blood loss of hemostasis, compared with 1.98. + -. 0.11g of the medical gauze group and 3.39. + -. 0.12g of the blank group; the blood loss of the experimental group is obviously reduced, and the difference has statistical significance (P is less than 0.05). Therefore, the degradable hemostatic bag capable of carrying the medicine of the utility model has better hemostatic effect.
The above is a detailed description of the preferred embodiments of the present invention, and those skilled in the art should understand that the present invention is not limited by the above embodiments. Modifications and additions to the above description, which may occur to persons skilled in the art, are considered to be within the scope of the invention. Any modification, equivalent replacement, and improvement made by those skilled in the art within the spirit and principle of the present invention should be included in the protection scope of the claims of the present invention.
Claims (8)
1. The degradable hemostatic bag capable of carrying the medicine is characterized in that the degradable hemostatic bag is a bag body (1) with a cavity (2), and a sealing door is arranged at an opening of the cavity (2);
the bag body (1) and the sealing door are made of hemostatic materials, and the cavity (2) is used for placing medicines.
2. The drug-loadable degradable hemostatic bag according to claim 1, wherein the bag body (1) is obtained by freeze-drying hydroxyethyl cellulose.
3. The drug-loadable degradable hemostatic bag according to claim 1, wherein the shape of the bag body (1) is cuboid or ellipsoid.
4. The drug-loadable degradable hemostatic bag according to claim 3, wherein when the bag body (1) is a cuboid, the edges of the cuboid are pre-formed with rounded corners.
5. The drug-loadable degradable hemostatic sac according to claim 1, wherein the sealing door is hinged with the sac body (1).
6. The drug-loadable degradable hemostatic bag according to claim 1, wherein the sealing door is detachably connected to the bag body (1).
7. The drug-loadable degradable hemostatic bag according to claim 1, wherein the wall thickness of the bag body (1) is 2-4 mm.
8. The degradable hemostatic bag capable of carrying drugs according to claim 1, wherein the volume of the cavity (2) is 0.2-1 cm3。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202022964810.2U CN215018250U (en) | 2020-12-11 | 2020-12-11 | Degradable hemostatic bag capable of carrying medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202022964810.2U CN215018250U (en) | 2020-12-11 | 2020-12-11 | Degradable hemostatic bag capable of carrying medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN215018250U true CN215018250U (en) | 2021-12-07 |
Family
ID=79214866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202022964810.2U Active CN215018250U (en) | 2020-12-11 | 2020-12-11 | Degradable hemostatic bag capable of carrying medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN215018250U (en) |
-
2020
- 2020-12-11 CN CN202022964810.2U patent/CN215018250U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10314937B2 (en) | Biocompatible hemostatic product and preparation method thereof | |
| Whipple | Radical surgery for certain cases of pancreatic fibrosis associated with calcareous deposits | |
| CN104888263B (en) | Biocompatible hemostatic prevents adhesion, promoting healing, the closed modified starch material of surgery | |
| KR101105081B1 (en) | Tissue Dressing Assemblies, Systems, and Methods Formed from Hydrophilic Polymer Sponge Structures such as Chitosan | |
| US7153518B2 (en) | Processed soft tissue for topical or internal application | |
| AU2017203958B2 (en) | Hemostatic device | |
| ES2368518T3 (en) | BIODEGRADABLE BIODEGRADABLE NON-TOXIC BIOLOGICAL ADHESIVE FOR USE IN ABDOMINAL SURGERY. | |
| CN106913902A (en) | Polysaccharide based aquagel | |
| KR20070088803A (en) | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chitosan | |
| ZA200605125B (en) | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan | |
| JP2008503308A (en) | Apparatus, system and method for tissue deviation or separation | |
| CN102665733A (en) | Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders | |
| Georgiade et al. | Late development of hematoma around a breast implant, necessitating removal | |
| CN101507731A (en) | Chitosan uterus-neck antibiotic film and preparation method thereof | |
| Moscona et al. | In favor of healing by secondary intention after excision of medial canthal basal cell carcinoma | |
| CN215018250U (en) | Degradable hemostatic bag capable of carrying medicine | |
| US20040037866A1 (en) | Composition and method for the treatment and prevention of adhesions | |
| Iorio et al. | Short-term results of treating primary and recurrent anal fistulas with a novel extracellular matrix derived from porcine urinary bladder | |
| ES2648090T3 (en) | Use of gelled PRP (platelet gel) for volumetric breast reconstruction | |
| CN104000652A (en) | Absorbable drug release bag film capable of preventing adhesion | |
| WO1999018931A1 (en) | Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids | |
| Savrin et al. | Mass lesion of the breast after augmentation mammoplasty | |
| Osada et al. | Coverage of free flap vascular pedicles by basic fibroblast growth factor-impregnated collagen-gelatin sponge without skin graft | |
| CN112138202A (en) | Temperature sensitive digestive tract mucosa protective adhesive | |
| Economou et al. | Prophylactic measures in the spread of carcinoma of the colon and rectum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |